World Health Organization & Moderna

World Health Organization: The World Health Organization (WHO) has declared the outbreak a public health emergency and is involved in monitoring cases and coordinating the global health response.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

World Health Organization: The World Health Organization is leading the international response to the Ebola outbreak in the Democratic Republic of the Congo, revising its risk assessment to 'very high' nationally and launching a $518 million plan to combat the spread. Its efforts are hampered by conflict and community mistrust.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

World Health Organization: The World Health Organization has declared the Ebola outbreak a public health emergency of international concern, providing funds, dispatching teams, and coordinating global response efforts while expressing deep concern over the outbreak's scale and speed.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

World Health Organization: Coordinating vaccine allocation and clinical trials, but facing uncertainty about vaccine efficacy against the current strain. Its guidance is critical for the response.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

World Health Organization: Leading the international response, declaring a PHEIC, recommending vaccine trials, and adding a diagnostic test to its Emergency Use Listing. Its credibility is tied to the success of the response.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

World Health Organization: The World Health Organization is coordinating the vaccine supply and recommending clinical trials, playing a key role in the global response. Its actions are critical to controlling the outbreak.

Moderna: Moderna is developing an mRNA-based vaccine targeting the Bundibugyo strain, currently in clinical trials. Its progress could offer a more specific solution and enhance its vaccine portfolio.

World Health Organization: The World Health Organization has declared the Ebola situation a Public Health Emergency of International Concern, highlighting the severity of the outbreak.

Moderna: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.

World Health Organization: WHO's strain selection process may benefit from faster mRNA vaccine production.

Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.

World Health Organization: Mentioned in one text regarding a statement on Moderna vaccine; not a major actor.

Moderna: One of the vaccine manufacturers; similar to Pfizer, minimal direct impact.